Tag: Pharnext
Pharnext: raises 1ME by issuing OCEANE-BSA bonds
(CercleFinance.com) – Pharnext announces a fundraising of one million euros through the issue of OCEANE-BSA bonds, with a nominal value of €1,000,000, subscribed by Global Tech Opportunities 13. The issue…
Pharnext: Shareholders approve the appointment of Guy-Charles Fanneau de La Horie to the Supervisory Board
By Hector Chaunu Published on 07/10/2023 at 08:47 Photo credit © ChaunuPictures (Boursier.com) — Pharnext a biopharmaceutical company…
PHARNEXT: Reduction of the par value of the share – 2023-07-06 at 20:00
PARIS, France, July 6, 2023 at 8:00 p.m. (CET) – Pharnext SA (FR001400GUN7 – ALPHA) (the “Company”), a late-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases with no satisfactory…
PHARNEXT: The latest results from CMTMe, a digital study evaluating the lifestyle of patients with Charcot-Marie-Tooth diseases (CMTs), will be presented at the 2023 Annual Meeting of the Peripheral Nerve Society (‘PNS’) – 14/ 06/2023 at 08:30
PARIS, France, June 14, 2023 at 8:30 a.m. (CET) – Pharnext SA (FR001400GUN7 – ALPHA) (the “Company”), a late-stage biopharmaceutical company developing new therapies for neurodegenerative diseases with no satisfactory…
Pharnext supports and participates in the First European Conference of Charcot-Marie-Tooth disease specialists
By Claude Leguilloux Published on 06/08/2023 at 08:43 Photo credit © ChaunuPictures (Boursier.com) — Pharnext SA, a late-stage…
PHARNEXT: Edison Investment Research publishes a research report on Pharnext – 05/22/2023 at 08:30
PARIS, France, May 22, 2023 at 8:30 a.m. (CET) – Pharnext SCA (FR001400GUN7 – ALPHA) (the “Company”), a late-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases with no satisfactory…
PHARNEXT: Start of trading of shares resulting from the combination and other capital transactions – 05/10/2023 at 08:30
Consolidation by way of exchange of 10,000 old shares for 1 new share Effective date of the consolidation on Wednesday, May 10, 2023 Resumption of the right to exercise securities…
PHARNEXT: Data on the impact of fatigue in patients with Charcot-Marie-Tooth disease, from the CMT and Me digital study, will be presented during a webinar organized with CMT UK – 03/23/ 2023 at 08:30
PARIS, France, March 23, 2023 at 8:30 a.m. (CET) – Pharnext SCA (FR001400BV89 – ALPHA) (the “Company”), a late-stage biopharmaceutical company developing new therapies for neurodegenerative diseases with no satisfactory…
PHARNEXT: Pharnext supports and participates in the 27th Days of the Francophone Society of the Peripheral Nerve (SFNP) in Paris – 03/06/2023 at 08:30
PARIS, France, March 6, 2023 at 8:30 a.m. (CET) – Pharnext SCA (FR001400BV89 – ALPHA) (the “Company”), a late-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases with no satisfactory…
PHARNEXT: Availability of documents relating to the combined general meeting of February 24, 2023 – 02/10/2023 at 6:00 p.m.
PARIS, France, February 10, 2023 at 6:00 p.m. (CET) – Pharnext SA (FR001400BV89 – ALPHA) (the “Company”), a biopharmaceutical company at an advanced clinical stage developing new therapies for neurodegenerative…
Pharnext could become an SCA controlled by Neovacs
Through Alexandra Saintpierre Published on 01/24/2023 at 2:29 p.m. Photo credit © NissierPictures …
PHARNEXT: Pharnext raises 1 MEUR per OCEANE-BSA issue – 01/25/2023 at 6:30 pm
PARIS, France, January 25, 2023 at 6:30 p.m. (CET) – Pharnext SA (FR001400BV89 – ALPHA) (the “Company”), a late-stage biopharmaceutical company developing new therapies for neurodegenerative diseases without satisfactory therapeutic…